The Molecular Mechanism of CMV-driven NKG2C+NK Cell Expansion in Human

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04298502

Enrollment

Registered

2020-03-06

Start date

2020-01-01

Completion date

2021-12-31

Last updated

2020-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Leukemia, CMV Viremia, Hematopoietic Stem Cell Transplantation

Brief summary

This is an observation study to investigate the molecular mechanism of NKG2C+NK cell expansion after HCMV infection

Detailed description

According to the changes of molecular and gene expression in NK cells at different time points after infection, we want to find out the mechanism by which HCMV promotes the expansion of NKG2C + NK cells.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

1. AML or MDS or CML or ALL undergoing haploidentical stem cells transplantation 2. No severe organ dysfunction or failure 3. Subjects must be capable of, and willing to provide written informed consent to participate in the study. Subjects unable to provide written informed consent by themselves may be consented through their legal representative.

Exclusion criteria

1. Participation in another industry-sponsored clinical study where treatment for CMV is already specified by the study protocol. 2. Patients received other adoptive immunotherapy such as donor lymphocyte infusion (DLI), Epstein-Barr virus (EBV)-specific T cells and so on.

Design outcomes

Primary

Measure	Time frame	Description
CMV viremia	2 moths post-transplantation	CMV-DNA\>1.0x10\^3 cpies/mL

Countries

China

Contacts

Primary ContactXiangyu Zhao, M.D., PhD

xyz80421@126.com+8610-88325949

Outcome results